JP4889897B2 - トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形 - Google Patents

トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形 Download PDF

Info

Publication number
JP4889897B2
JP4889897B2 JP2001504359A JP2001504359A JP4889897B2 JP 4889897 B2 JP4889897 B2 JP 4889897B2 JP 2001504359 A JP2001504359 A JP 2001504359A JP 2001504359 A JP2001504359 A JP 2001504359A JP 4889897 B2 JP4889897 B2 JP 4889897B2
Authority
JP
Japan
Prior art keywords
unit according
oral dosage
diclofenac
dosage unit
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001504359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003502360A5 (enExample
JP2003502360A (ja
Inventor
バートロメーウス・ヨハネス
ツィーグレル・イリス
Original Assignee
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7911586&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4889897(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング
Publication of JP2003502360A publication Critical patent/JP2003502360A/ja
Publication of JP2003502360A5 publication Critical patent/JP2003502360A5/ja
Application granted granted Critical
Publication of JP4889897B2 publication Critical patent/JP4889897B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2001504359A 1999-06-17 2000-06-13 トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形 Expired - Fee Related JP4889897B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19927689.7 1999-06-17
DE19927689A DE19927689A1 (de) 1999-06-17 1999-06-17 Orale Darreichungsformen zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
PCT/EP2000/005386 WO2000078294A2 (de) 1999-06-17 2000-06-13 Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac

Publications (3)

Publication Number Publication Date
JP2003502360A JP2003502360A (ja) 2003-01-21
JP2003502360A5 JP2003502360A5 (enExample) 2011-08-25
JP4889897B2 true JP4889897B2 (ja) 2012-03-07

Family

ID=7911586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001504359A Expired - Fee Related JP4889897B2 (ja) 1999-06-17 2000-06-13 トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形

Country Status (15)

Country Link
US (1) US20020156133A1 (enExample)
EP (1) EP1185253B1 (enExample)
JP (1) JP4889897B2 (enExample)
AT (1) ATE260650T1 (enExample)
AU (1) AU778151B2 (enExample)
CA (1) CA2377174C (enExample)
DE (2) DE19927689A1 (enExample)
DK (1) DK1185253T3 (enExample)
ES (1) ES2215680T3 (enExample)
HK (1) HK1045113A1 (enExample)
HU (1) HUP0201687A3 (enExample)
MX (1) MXPA01013046A (enExample)
NZ (1) NZ516593A (enExample)
PT (1) PT1185253E (enExample)
WO (1) WO2000078294A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
CN101257894A (zh) 2005-07-07 2008-09-03 法纳姆公司 高水溶性药物的缓释药物组合物
US20070009591A1 (en) * 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
EP1785412A1 (en) * 2005-11-14 2007-05-16 IPCA Laboratories Limited Tramadol recovery process
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤
HRP20120700T1 (hr) 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
DE102008056312A1 (de) 2008-11-07 2010-05-12 Biogenerics Pharma Gmbh Verwendung von Mikrotabletten als Lebens-und Futtermittelzusatz
KR20130129070A (ko) * 2010-07-12 2013-11-27 융신 파마슈티칼 인더스트리얼 컴파니 리미티드 트라마돌의 디클로페낙 염
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN110755396B (zh) * 2019-12-06 2022-04-08 北京悦康科创医药科技股份有限公司 一种布洛芬缓释小丸及其制备方法
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6251625A (ja) * 1985-08-28 1987-03-06 ユ−ロセルテイツク・エス・ア− 医薬組成物
JPS6348219A (ja) * 1986-08-13 1988-02-29 ドクトル　カルル　ト−マエ　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング ジピリダモル又はモピダモルと、０―アセチルサリチル酸とを含む製薬組成物、及びその製造方法
EP0546676A1 (en) * 1991-10-30 1993-06-16 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
WO1998017268A2 (en) * 1996-10-24 1998-04-30 Algos Pharmaceutical Corporation Method of alleviating pain by means of combining tramadol with an nmda antagonist

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6251625A (ja) * 1985-08-28 1987-03-06 ユ−ロセルテイツク・エス・ア− 医薬組成物
JPS6348219A (ja) * 1986-08-13 1988-02-29 ドクトル　カルル　ト−マエ　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング ジピリダモル又はモピダモルと、０―アセチルサリチル酸とを含む製薬組成物、及びその製造方法
EP0546676A1 (en) * 1991-10-30 1993-06-16 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
WO1998017268A2 (en) * 1996-10-24 1998-04-30 Algos Pharmaceutical Corporation Method of alleviating pain by means of combining tramadol with an nmda antagonist

Also Published As

Publication number Publication date
NZ516593A (en) 2003-08-29
ATE260650T1 (de) 2004-03-15
CA2377174C (en) 2009-07-28
EP1185253B1 (de) 2004-03-03
DE19927689A1 (de) 2000-12-21
DE50005529D1 (de) 2004-04-08
ES2215680T3 (es) 2004-10-16
WO2000078294A2 (de) 2000-12-28
WO2000078294A3 (de) 2001-03-29
AU778151B2 (en) 2004-11-18
MXPA01013046A (es) 2002-06-04
CA2377174A1 (en) 2000-12-28
PT1185253E (pt) 2004-07-30
DK1185253T3 (da) 2004-04-05
JP2003502360A (ja) 2003-01-21
US20020156133A1 (en) 2002-10-24
HUP0201687A2 (en) 2002-09-28
HK1045113A1 (zh) 2002-11-15
HUP0201687A3 (en) 2005-07-28
AU5680500A (en) 2001-01-09
EP1185253A2 (de) 2002-03-13

Similar Documents

Publication Publication Date Title
JP4889897B2 (ja) トラマドールとジクロフェナクの固定組合せ物を投与するための経口投与形
CA2348090C (en) Oral pulsed dose drug delivery system
EP1940361B1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties
KR100735509B1 (ko) 지연 작용을 갖는 경구 약제학적 투여 형태
US7611730B2 (en) Tramadol-based medicament
Murugesan et al. Oral modified drug release solid dosage form with special reference to design; an overview
JP2005508922A (ja) プロプラノロールの時限徐放性多粒子剤型
JP2003503341A (ja) 少なくとも一つの適時パルスを生ずる制御された放出用の医薬投与形態
HU219449B (hu) Eljárás bélbetegségek kezelésére alkalmas késleltetett hatóanyag-leadású orális gyógyászati készítmények előállítására
US10561602B2 (en) Controlled extended release pregabalin
US20050226927A1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
JP2005526739A (ja) コレステロール濃度を低下させる活性成分を含み、活性成分が遅延放出される薬剤
US20050220873A1 (en) Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
JP2004512298A (ja) 遅延及び持続放出製剤、及びそれを使用する方法
US8173164B2 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
US20050220874A1 (en) Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20050220863A1 (en) Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
KR20040005257A (ko) 방출제어형 약제학적 조성물
US20050220864A1 (en) Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
KR20020031421A (ko) 경구 투여 형태

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070604

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110513

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110614

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110621

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111129

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111214

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141222

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141222

Year of fee payment: 3

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

LAPS Cancellation because of no payment of annual fees